| Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan HJWL Aerts, AAW van Baardwijk, SF Petit, C Offermann, J van Loon, ... Radiotherapy and oncology 91 (3), 386-392, 2009 | 227 | 2009 |
| Selective nodal irradiation on basis of 18FDG-PET scans in limited-disease small-cell lung cancer: a prospective study J van Loon, D De Ruysscher, R Wanders, L Boersma, J Simons, ... International Journal of Radiation Oncology* Biology* Physics 77 (2), 329-336, 2010 | 188 | 2010 |
| PET imaging of hypoxia using [18F]HX4: a phase I trial J van Loon, MHM Janssen, M Öllers, HJWL Aerts, L Dubois, ... European journal of nuclear medicine and molecular imaging 37, 1663-1668, 2010 | 133 | 2010 |
| Evaluation of novel radiotherapy technologies: what evidence is needed to assess their clinical and cost effectiveness, and how should we get it? J van Loon, J Grutters, F Macbeth The lancet oncology 13 (4), e169-e177, 2012 | 105 | 2012 |
| 18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study J van Loon, C Offermann, G Bosmans, R Wanders, A Dekker, J Borger, ... Radiotherapy and Oncology 87 (1), 49-54, 2008 | 90 | 2008 |
| Comparative evaluation of autocontouring in clinical practice: a practical method using the Turing test MJ Gooding, AJ Smith, M Tariq, P Aljabar, D Peressutti, J Van der Stoep, ... Medical physics 45 (11), 5105-5115, 2018 | 81 | 2018 |
| Microscopic disease extension in three dimensions for non–small-cell lung cancer: development of a prediction model using pathology-validated positron emission tomography and … J van Loon, C Siedschlag, J Stroom, H Blauwgeers, RJ van Suylen, ... International Journal of Radiation Oncology* Biology* Physics 82 (1), 448-456, 2012 | 81 | 2012 |
| Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial PJAM Brouwers, E van Werkhoven, H Bartelink, A Fourquet, C Lemanski, ... Radiotherapy and Oncology 128 (3), 434-441, 2018 | 63 | 2018 |
| How public health services pay for radiotherapy in Europe: an ESTRO–HERO analysis of reimbursement Y Lievens, N Defourny, J Corral, C Gasparotto, C Grau, JM Borras, ... The Lancet Oncology 21 (1), e42-e54, 2020 | 61 | 2020 |
| PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer J van Loon, AJG Even, HJWL Aerts, M Öllers, F Hoebers, W van Elmpt, ... Radiotherapy and Oncology 122 (2), 267-273, 2017 | 61 | 2017 |
| Stage III non-small cell lung cancer in the elderly: patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice EJM Driessen, GP Bootsma, LEL Hendriks, FWPJ van den Berkmortel, ... Radiotherapy and Oncology 121 (1), 26-31, 2016 | 60 | 2016 |
| Spacers in radiotherapy treatment of prostate cancer: is reduction of toxicity cost-effective? BGL Vanneste, M Pijls-Johannesma, L Van De Voorde, EN van Lin, ... Radiotherapy and Oncology 114 (2), 276-281, 2015 | 60 | 2015 |
| Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancer J van Loon, A van Baardwijk, L Boersma, M Öllers, P Lambin, ... Cancer treatment reviews 37 (5), 331-343, 2011 | 59 | 2011 |
| Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study SF Petit, HJWL Aerts, JGM van Loon, C Offermann, R Houben, B Winkens, ... Radiotherapy and Oncology 91 (3), 393-398, 2009 | 59 | 2009 |
| Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage I to III small cell lung cancer B Reymen, J Van Loon, A van Baardwijk, R Wanders, J Borger, ... International Journal of Radiation Oncology* Biology* Physics 85 (5), 1319-1324, 2013 | 57 | 2013 |
| Follow-up with 18FDG-PET–CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung … J van Loon, J Grutters, R Wanders, L Boersma, M Oellers, AM Dingemans, ... European Journal of Cancer 45 (4), 588-595, 2009 | 57 | 2009 |
| 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation J van Loon, JPC Grutters, R Wanders, L Boersma, AMC Dingemans, ... European Journal of Cancer 46 (1), 110-119, 2010 | 55 | 2010 |
| Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I–III small cell lung cancer: a hypothesis generating study J van Loon, C Offermann, M Öllers, W van Elmpt, E Vegt, A Rahmy, ... Radiotherapy and Oncology 99 (2), 172-175, 2011 | 52 | 2011 |
| Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990–2014): Disparities between younger and older patients EJ Driessen, MJ Aarts, GP Bootsma, JG van Loon, ML Janssen-Heijnen Lung Cancer 108, 198-204, 2017 | 46 | 2017 |
| National costs and resource requirements of external beam radiotherapy: a time-driven activity-based costing model from the ESTRO-HERO project N Defourny, L Perrier, JM Borras, M Coffey, J Corral, S Hoozée, ... Radiotherapy and Oncology 138, 187-194, 2019 | 44 | 2019 |
